» Articles » PMID: 38132337

Expanding Roles of the E2F-RB-p53 Pathway in Tumor Suppression

Overview
Journal Biology (Basel)
Publisher MDPI
Specialty Biology
Date 2023 Dec 22
PMID 38132337
Authors
Affiliations
Soon will be listed here.
Abstract

The transcription factor E2F links the RB pathway to the p53 pathway upon loss of function of pRB, thereby playing a pivotal role in the suppression of tumorigenesis. E2F fulfills a major role in cell proliferation by controlling a variety of growth-associated genes. The activity of E2F is controlled by the tumor suppressor pRB, which binds to E2F and actively suppresses target gene expression, thereby restraining cell proliferation. Signaling pathways originating from growth stimulative and growth suppressive signals converge on pRB (the RB pathway) to regulate E2F activity. In most cancers, the function of pRB is compromised by oncogenic mutations, and E2F activity is enhanced, thereby facilitating cell proliferation to promote tumorigenesis. Upon such events, E2F activates the tumor suppressor gene, leading to activation of the tumor suppressor p53 to protect cells from tumorigenesis. ARF inactivates MDM2, which facilitates degradation of p53 through proteasome by ubiquitination (the p53 pathway). P53 suppresses tumorigenesis by inducing cellular senescence or apoptosis. Hence, in almost all cancers, the p53 pathway is also disabled. Here we will introduce the canonical functions of the RB-E2F-p53 pathway first and then the non-classical functions of each component, which may be relevant to cancer biology.

Citing Articles

Pin1 as a central node in oncogenic signaling: Mechanistic insights and clinical prospects (Review).

Lei S, Luo M, Wang Y Mol Med Rep. 2025; 31(3).

PMID: 39886975 PMC: 11795255. DOI: 10.3892/mmr.2025.13445.


A novel piperine derivative HJ-23 exhibits anti-colorectal cancer effects by activating the p53 pathway.

Zhang M, Liu R, Jiang W, Li H, Zhang S, Cheng W Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39718615 DOI: 10.1007/s00210-024-03707-2.


Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer.

Huang F, Li K, Chen Z, Cui Z, Hankey W, Fang K Oncogene. 2024; 44(8):481-493.

PMID: 39613933 DOI: 10.1038/s41388-024-03239-2.


Potential Target of CDK6 Signaling Pathway for Cancer Treatment.

Basnet R, Amissah O, Basnet B, Huang R, Sun Y, Habimana J Curr Drug Targets. 2024; 25(11):724-739.

PMID: 39039674 DOI: 10.2174/0113894501313781240627062206.


P53 and pRB induction improves response to radiation therapy in HPV-positive laryngeal squamous cell carcinoma.

Ding W, Cai W, Wang H Clinics (Sao Paulo). 2024; 79:100415.

PMID: 38897099 PMC: 11237859. DOI: 10.1016/j.clinsp.2024.100415.

References
1.
Valente L, Gray D, Michalak E, Pinon-Hofbauer J, Egle A, Scott C . p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Rep. 2013; 3(5):1339-45. DOI: 10.1016/j.celrep.2013.04.012. View

2.
Lin X, Guan H, Huang Z, Liu J, Li H, Wei G . Downregulation of Bcl-2 expression by miR-34a mediates palmitate-induced Min6 cells apoptosis. J Diabetes Res. 2014; 2014:258695. PMC: 4009326. DOI: 10.1155/2014/258695. View

3.
Seillier M, Peuget S, Gayet O, Gauthier C, NGuessan P, Monte M . TP53INP1, a tumor suppressor, interacts with LC3 and ATG8-family proteins through the LC3-interacting region (LIR) and promotes autophagy-dependent cell death. Cell Death Differ. 2012; 19(9):1525-35. PMC: 3422476. DOI: 10.1038/cdd.2012.30. View

4.
Lin W, Lin F, Nevins J . Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. Genes Dev. 2001; 15(14):1833-44. PMC: 312742. View

5.
Laine A, Westermarck J . Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells. Clin Cancer Res. 2014; 20(14):3644-50. DOI: 10.1158/1078-0432.CCR-13-1942. View